Although targeted tyrosine kinase inhibitors have been used in clinical routine since 2011 with very good outcomes in BRAF V600-mutated melanoma, BRAF-mutated mCRC proved to be less sensitive to monotherapy [32, 33]. This evidence concerns the gene BRAF and melanoma.